Ginkgo Bioworks Holdings Operating Margin 2020-2022 | DNA

Current and historical operating margin for Ginkgo Bioworks Holdings (DNA) over the last 10 years. The current operating profit margin for Ginkgo Bioworks Holdings as of March 31, 2022 is 0.00%.
Ginkgo Bioworks Holdings Operating Margin Historical Data
Date TTM Revenue TTM Operating Income Operating Margin
2021-12-31 $0.31B $-1.83B -582.17%
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $4.228B $0.314B
Ginkgo Bioworks platform is enabling biotechnology applications across diverse markets, from food and agriculture to industrial chemicals to pharmaceuticals. Ginkgo Bioworks, formerly known as Soaring Eagle Acquisition Corp., is based in NEW YORK.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $163.597B 9.95
Bio-Rad Laboratories (BIO.B) United States $14.907B 32.33
QIAGEN (QGEN) Netherlands $10.865B 17.15
Biohaven Pharmaceutical Holding (BHVN) United States $10.248B 0.00
Arcus Biosciences (RCUS) United States $1.901B 48.18
Emergent Biosolutions (EBS) United States $1.599B 6.85
Myovant Sciences (MYOV) United Kingdom $1.236B 0.00
Zymeworks (ZYME) Canada $0.320B 0.00
Gelesis Holdings (GLS) United States $0.114B 0.00
Enzo Biochem (ENZ) United States $0.104B 0.00
Ambrx Biopharma (AMAM) United States $0.103B 0.00
SQZ Biotechnologies (SQZ) United States $0.087B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.000B 0.00